Hematogenous micrometastases in osteosarcoma patients

Clinical Cancer Research

Volumn 11, Issue 13, 2005, Pages 4666-4673

  Bruland, Øyvind S ^a,b   Høifødt, Hanne ^b   Sæter, Gunnar ^b   Smeland, Sigbjørn ^b   Fodstad, Øystein ^a,b,c  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; CELL MEMBRANE MARKER;

ADOLESCENT; ADULT; ARTICLE; BLOOD; BONE MARROW; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER LOCALIZATION; CANCER STAGING; CELL COUNT; CHILD; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLUORESCENCE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMAGNETIC SEPARATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; NUDE MOUSE; OSTEOSARCOMA; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; TUMOR CELL;

ADOLESCENT; ADULT; ANIMALS; BONE MARROW EXAMINATION; BONE MARROW NEOPLASMS; BONE NEOPLASMS; CHILD; FEMALE; HUMANS; IMMUNOMAGNETIC SEPARATION; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; OSTEOSARCOMA; SURVIVAL ANALYSIS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 27644458324     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0165     Document Type: Article

References (47)

1. Malawer MM, Link MP, Donaldson SS. Sarcomas of bone. In: Devita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven Publishers; 1997. p. 1789-852.
2. Souhami R, Cannon SR. Osteosarcoma. Oxford textbook of oncology. In: Peckham M, Pinedo HM, Veronesi U, editors. Oxford: Oxford University Press; 1995. p. 1969-76.
3. Cade S. Osteogenic sarcoma: a study based on 133 patients. J R Coll Surg Edinb 1955;1:79-111.
4. Dahlin D, Unni K. Osteogenic sarcoma of bone and its important recognizable varieties. Am J Surg Pathol 1977;1:61-72.
5. Huvos AG. Osteogenic sarcoma. In: Huvos AG, editor. Bone tumors. Diagnosis, treatment and prognosis. Philadelphia: WB Saunders; 1991. p. 85-155.
6. Harter KW. Osteosarcoma and less common sarcomas of childhood. In: Cassady JR, editor. Radiation therapy in pediatric oncology. Springer Verlag, Berlin 1994. p. 305-17.
7. Bruland ØS, Pihl A. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer 1997;33:1725-31.
8. Rosen G, Marcove RC, Caparros B. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979;43:2163-77.
9. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5-15.
10. Sæter G, Alvegård TA, Elomaa I, et al. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single agent high-dose methotrexate. A Scandinavian Sarcoma Group Study. J Clin Oncol 1991;9:1766-75.
11. Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities: results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 1993;72:3227-38.
12. Winkler K, Bielack S, Delling G, et al. Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86). Cancer 1990;66:1703-10.
13. Roth JA, Putnam JBJ, Wesley MN, Rosenberg SA. Differing determinants of prognosis following resection of pulmonary metastases from osteogenic and soft tissue sarcoma patients. Cancer 1985;55:1361-6.
14. Beattie EJ, Harvey JC, Marcove R, Martini N. Results of multiple pulmonary resections for metastatic osteogenic sarcoma after two decades. J Surg Oncol 1991;46:154-5.
15. van Rijk Zwikker GL, Nooy MA, Taminiau A, Kappetein AP, Huysmans HA. Pulmonary metastasectomy in patients with osteosarcoma. Eur J Cardiothorac Surg 1991;5:406-9.
16. Meyers PA, Heller G, Healey JH, et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 1993;11:449-53.
17. Bacci G, Briccoli A, Picci P, et al. Osteosarcoma of the extremities metastatic at presentation: results obtained with primary chemotherapy followed by simultaneous resection of the primary and metastatic lesions. Cancer J 1990;3:213-8.
18. Sæter G, Bruland ØS, Follerås G, Boysen M, Høie J. Extremity and non-extremity high grade osteosarcoma. The Norwegian Radium Hospital experience during the modern chemotherapy era. Acta Oncol 1996;35:129-34.
19. 3Thymidine labeling in the peripheral blood of normal and sarcoma patients. Thesis: University of Minnesota, 1978.
20. Kaiser TE. The detection of tritiated thymidine labeled cells in the peripheral blood of sarcoma patients and the nature of these cells bearing prognostic significance for sarcoma patients. Thesis: University of Minnesota, 1985.
21. Foss PO, Messelt OT, Efskind J. Isolation of cancer cells from blood and thoracic duct lymph by filtration. Surgery 1963;53:241-6.
22. Foss PO, Brennhovd IO, Messelt OT, Efskind J, Liverud K. Invasion of tumor cells into the bloodstream caused by palpation or biopsy of the tumor. Surgery 1966;59:691-5.
23. Beiske K, Myklebust AT, Aamdal S, et al. Detection of bone marrow metastases in small cell lung cancer patients. Comparison of immunological methods. Am J Pathology 1992;141:531-8.
24. Mansi JL, Gogas H, Bliss JM, et al. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 1999;354:197-202.
25. Pantel K, Cote RJ, Fodstad Ø. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 1999;91:1113-24.
26. Wiedswang G, Borgen E, Kaaresen R, et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 2003;21:3469-78.
27. Pantel K, Muller V, Auer M, et al. Detection and clinical implications of early systemic tumor cell dissemination in breast cancer. Clin Cancer Res 2003;9:6326-34.
28. Ghossein RA, Bhattacharya S. Molecular detection and characterisation of circulating tumour cells and micrometastases in solid tumours. Eur J Cancer 2000;36:1681-94.
29. Taback B, Chan AD, Kuo CT, et al. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease. Cancer Res 2001;61:8845-50.
30. Funke I, Schraut W. Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. J Clin Oncol 1998;16:557-66.
31. Marth C, Kisic J, Kærn J, Tropė C, Fodstad Ø. Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian cancer do not predict prognosis. Cancer 2002;94:846-52.
32. Flatmark K, Bjørnland K, Johannessen HO, et al. Immunomagnetic detection of micrometastatic cells in bone marrow of colorectal cancer patients. Clin Cancer Res 2002;8:444-9.
33. Faye R, Aamdal S, Høifødt HK, et al. Immunomagnetic detection and clinical significance of micrometastatic tumor cells in malignant melanoma patients. Clin Cancer Res 2004;15:4134-49.
34. Bruland ØS, Fodstad Ø, Funderud S, Pihl A. New monoclonal antibodies specific for human sarcomas. Int J Cancer 1986;38:27-31.
35. Bruland ØS, Fodstad Ø, Stenwig E, Pihl A. Expression and characteristics of a novel human osteosarcoma-associated cell surface antigen. Cancer Res 1988;48:5302-9.
36. Bruland ØS, Fodstad Ø, Skretting A, Pihl A. Selective radiolocalization of two radiolabelled anti-sarcoma monoclonal antibodies in human osteosarcoma xenografts. Br J Cancer 1987;56:21-5.
37. Bruland ØS, Aas M, Fodstad Ø, et al. Immunoscintigraphy of bone sarcomas. Results in five patients. Eur J Cancer 1994;30:1484-9.
38. Morgan AC Jr, Galloway DR, Reisfeld RA. Production and characterization of a monoclonal antibody to a melanoma specific glycoprotein. Hybridoma 1981;1:27-36.
39. Godal A, Bruland OS, Haug E, Aas M, Fodstad O. Unexpected expression of the 250 kD melanoma-associated antigen in human sarcoma cells. Br J Cancer 1986;53:839-41.
40. Fagnou C, Michon J, Peter M, et al. Presence of tumor cells in bone marrow but not in blood is associated with adverse prognosis in patients with Ewing's tumor. J Clin Oncol 1998;16:1707-11.
41. Athale UH, Shurtleff SA, Jenkins JJ, et al. Use of reverse transcriptase polymerase chain reaction for diagnosis and staging of alveolar rhabdomyosarcoma, Ewing sarcoma family of tumors, and desmoplastic small round cell tumor. J Pediatr Hematol Oncol 2001;23:99-104.
42. Schleiermacher G, Peter M, Oberlin O, et al. Increased risk of systemic relapse associated with bone marrow micrometastasis and circulating tumor cells in localized Ewing tumor. J Clin Oncol 2003;21:85-91.
43. Gorlick R, Anderson P, Andrulis I, et al. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res 2003;9:5442-53.
44. Serra M, Scotlandi K, Reverter-Branchat G, et al. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol 2003;21:536-42.
45. Valabrega G, Fagioloi F, Corso S, et al. ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells. Br J Cancer 2003;88:396-400.
46. Serra M, Reverter-Branchat G, Maurici D, et al. Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann Oncol 2004;15:151-60.
47. Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expression of P-glycoprotein in high-grade osteosarcoma in relation to clinical outcome. N Engl J Med 1995;333:1380-5.